- Senior Investigator, Molecular Structure Section
Dr. Berger earned his B.S. in chemistry from City College of the City University of New York in 1968. He received his Ph.D. in biochemistry and molecular biology in 1973 from Cornell University. He went on to do a postdoctoral fellowship in the department of genetics, biochemistry, and neurobiology at Stanford University School of Medicine from 1973 to 1976 and another fellowship in the department of cellular and developmental immunology at Scripps Clinical and Research Foundation from 1976 to 1977. He was a staff scientist with the Cell Biology Group at the Worcester Foundation for Experimental Biology, Shrewsbury, Massachusetts, from 1977 to 1987. He joined the NIAID Laboratory of Viral Diseases in 1987 and became chief of the Molecular Structure Section in 1995.
American Academy of Microbiology Fellow; Bernard Fields Memorial Lectureship, CROI 2007;1st NIH World AIDS Day Award 2006; ISI Highly Cited Researcher, Breakthrough of the Year, Science 1996; AAAS-Newcomb Cleveland Prize 1997; Great Experiments; Kenneth Fong/Clontech Award; Novartis-Drew Award for Biomedical Science; Damon Runyon-Walter Winchell Foundation Most Prominent Alumni; AMA/NIAID Nathan Davis Award; NIH Outstanding Contributions to Education of Postbaccalaureate Trainees; Norman P Salzman Memorial Mentor Award in Virology, Honorable Mention
National Institutes of Health Interest Group Memberships
Virology Interest Group, Immunology Interest Group, Antibody Interest Group, Viral Hepatitis Interest Group
- (2016). Assembly and release of infectious hepatitis C virus involving unusual organization of the secretory pathway. World Journal of Hepatology. 8(19), 796-814.
- (2016). Humoral Antibody Responses to HIV Viral Proteins and to CD4 Among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort. AIDS RESEARCH AND HUMAN RETROVIRUSES. 32(12), 1187-1197.
- (2015). Finding fusin/CXCR4, the first "2nd receptor" for HIV entry. Frontiers in Immunology. 6,
- (2015). Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity. JOURNAL OF VIROLOGY. 89(13), 6685-6694.
- (2015). Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection. Current Opinion in HIV and AIDS. 10(3), 207-213.